SEHK:2142Biotechs
HBM Holdings (SEHK:2142): Valuation Check After Bristol Myers Squibb Collaboration Validates Growth Prospects
HBM Holdings (SEHK:2142) just landed a multi year global collaboration and license deal with Bristol Myers Squibb, tying its antibody discovery platform to potentially more than $1.1 billion in future payments.
See our latest analysis for HBM Holdings.
The market has already started to reprice that validation, with a 1 day share price return of 6.6 percent pushing HBM Holdings to HK$13.34. Its roughly 574 percent year to date share price return and nearly 896 percent 1 year total shareholder...